Related Experiment Video
Updated: Jul 20, 2026
09:03
Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
Published on: November 23, 2014
Angiogenesis in ischemic and neoplastic disorders.
1McKusick-Nathans Institute of Genetic Medicine and the Departments of Pediatrics and Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-3914, USA. gsemenza@jhmi.edu
Annual Review of Medicine
|October 3, 2002
Summary
Vascular development, including angiogenesis, is crucial for oxygen delivery. This process, regulated by hypoxia-inducible factor 1, is vital in diseases like cancer and heart disease.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Developmental Biology
Background:
- Vascular development involves vasculogenesis and angiogenesis for cellular oxygen supply.
- Adult angiogenesis responds to tissue hypoxia/ischemia, impacting ischemic heart disease and cancer progression.
- Hypoxia-inducible factor 1 (HIF-1) activation is a key molecular pathway induced by hypoxia/ischemia.
Purpose of the Study:
- To summarize the critical molecular pathways and therapeutic implications of angiogenesis.
- To highlight the role of HIF-1 in regulating angiogenic factors.
- To discuss the clinical evaluation of therapeutic strategies targeting angiogenesis.
Main Methods:
- Review of molecular pathways involved in vascular development.
- Analysis of the role of hypoxia and HIF-1 in angiogenesis.
- Examination of therapeutic strategies for ischemic and neoplastic tissues.
Main Results:
- Angiogenesis is essential for maintaining oxygenation in tissues.
- HIF-1 activation upregulates vascular endothelial growth factor (VEGF) and other pro-angiogenic factors.
- Therapeutic stimulation of angiogenesis in ischemic tissues and inhibition in tumors are under clinical investigation.
Conclusions:
- Angiogenesis is a critical process in both normal development and disease states.
- Targeting the HIF-1 pathway offers potential therapeutic benefits for cardiovascular diseases and cancer.
- Clinical trials are evaluating novel angiogenesis-modulating therapies.
Related Concept Videos
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...